Article

ZEISS MyoCare Portfolio: Efficacy Confirmed across Multiple Sites, Large Cohorts, and Various Ethnic Groups

ZEISS Vision Care Abstracts and Posters @ ARVO 2024 - Clinical Summary

28 May 2024 · 4 min read

Author Dr. Christina Böck-Maier Scientific and Medical Affairs | ZEISS Vision Care

Author Dr. Judith Ungewiss Scientific and Medical Affairs | ZEISS Vision Care

Highlights

Results from two on-going multicenter trials in Asian and Caucasian children show that ZEISS MyoCare and ZEISS MyoCare S spectacle lenses slow the progression of myopia as compared to ZEISS single vision spectacle lenses across all sites involving large samples and in both Asian and Caucasian children.

The prevalence of myopia and high myopia is continuing to rise globally, causing substantial health and financial burden to individuals and the society. Whilst exploration of strategies to prevent and slow the progression of myopia has gained momentum, to ensure translation of results to the wider population, it is crucial to establish a robust body of evidence from diverse ethnic groups, large samples, and multiple locations. Studies on myopia treatments involving Asians are many, but research on Caucasians remains limited.

ZEISS MyoCare lenses are being evaluated in multi-center trials in China and Europe for a comprehensive and robust evaluation of their effectiveness in slowing myopia. ZEISS MyoCare lenses incorporate cylindrical annular refractive elements (C.A.R.E.) and introduce simultaneous myopic defocus at the retina. At the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO’24), ZEISS Vision Care presented data from two on-going, 2-year prospective, double-masked, multi-center clinical trials. Results indicate that ZEISS MyoCare lenses slowed progression of myopia as compared to single vision spectacle lenses.

Overview trials

Trial 1 (NCT05288335)

240 Chinese children aged 6 to 13 years, spherical equivalent refractive error (SE) -0.75 D to -5.00 D, were randomly assigned to ZEISS single vision lenses (SV, N = 80), ZEISS MyoCare with C.A.R.E. mean surface power of +4.6 D and a central clear zone of 7 mm (N = 80), or ZEISS MyoCare S with C.A.R.E. mean surface power of +3.8 D and 9 mm central clear zone (N = 80).

Trial 2 (NCT05919654)

304 Caucasian children aged 6 to 13 years, SE -0.75 D to -5.00 D, past annual progression of at least -0.50 D, were randomly assigned to ZEISS single vision lenses (N = 152) or ZEISS MyoCare with C.A.R.E. mean surface power of +4.6 D and a central clear zone of 7 mm (N = 152).

Myopia progression with ZEISS MyoCare designs in Asian children (Trial 1)

After 12 months of lens wear, both ZEISS MyoCare and ZEISS MyoCare S significantly slowed the progression of myopia. The following average reductions were observed as compared to ZEISS single vision lenses. [1]

ZEISS MyoCare

0.31 D

(48%) average reduction of refractive error
0.13 mm

(41%) average reduction of axial length progression

ZEISS MyoCare S

0.29 D

(45%) average reduction of refractive error
0.11 mm

(34%) average reduction of axial length progression

Additionally, the risk of fast progression (-0.75D or worse) was significantly reduced, with only 17% and 14% of ZEISS MyoCare and ZEISS MyoCare S wearers experiencing fast progression compared to 51% of children wearing single vision lenses. [2]

Wear time and subjective assessment of vision were comparable to single vision lenses, indicating high acceptance. [3]

Interestingly, both ZEISS MyoCare and MyoCare S slowed myopia progression irrespective of the presence of parental myopia, unlike single vision lenses which showed greater progression in children with parental myopia. [4]

Myopia progression with ZEISS MyoCare in Caucasian children (Trial 2)

After 6 months of lens wear ZEISS MyoCare lenses resulted in a reduction of myopia progression by an average of 0.15 D (63%) for spherical equivalent error and 0.07 mm (77%) for axial length compared to ZEISS single vision lenses. [5]

0.15 D

(63%) average reduction of refractive error
0.07 mm

(77%) average reduction of axial length progression

Subjective vision rating (Trial 1 + 2)

In both trials vision with ZEISS MyoCare was subjectively rated as good or very good as follows [6]:

95%

of all participants for distance vision
93%

of all participants for near vision
96%

of all participants for dynamic vision

emmetropic progression ratio with ZEISS MyoCare

The Emmetropic Progression Ratio (EPR)

The ability of ZEISS MyoCare lenses to slow eye growth from that of a myopic eye to approach physiological growth observed in emmetropic eyes was reported as Emmetropic Progression Ratio (EPR) [7]. Published data on annual AL elongation for myopic and emmetropic eyes (> 1000 eyes each, age 7 – 12 years, Asian and Caucasian ethnicity respectively) were used to determine age-wise AL growth curves.

In trial 1, after 12-months of lens wear, both ZEISS MyoCare lenses slowed AL significantly and approached closer to AL growth of an emmetropic eye, with average EPRs of 70%* for ZEISS MyoCare and 68% for ZEISS MyoCare S. [7]

_{*EPR for ages 7-12 yr old children as sample size for ages 6 and 13 was small. When the entire sample of 6 to 13 years were considered, EPR for ZEISS MyoCare was 71%.}

¹
Chen, X., et al. (2024, May 5-9). Slowing myopia progression with cylindrical annular refractive elements (CARE) – 12-month interim results from a 2-year prospective multi-center trial [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Seattle, WA, United States.
²
Sankaridurg, P., et al. (2024, May 5-9). Probability of surviving fast progression and eye growth reversal after 1-year of spectacle wear with cylindrical annular refractive elements [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Seattle, WA, United States.
³
Rifai, K., et al. (2024, May 5-9). Subjective acceptance of spectacle lenses with cylindrical annular refractive elements (CARE) in Chinese children with myopia [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Seattle, WA, United States.
⁴
Boeck-Maier, C., et al. (2024, May 5-9). Impact of parental myopia on myopia control efficacy of spectacle lenses with cylindrical annular refractive elements (CARE) [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Seattle, WA, United States.
⁵
Alvarez-Peregrina, C., et al. (2024, May 5-9). Efficacy of a next-generation design of ophthalmic lenses for myopia control: Six-month results of the CEME Study [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Seattle, WA, United States.
⁶
Alvarez-Peregrina C., et al. (2024, April 12-14). Vision, confort y tiempo de adaptacion a un nuevo diseno de lente oftalmica para el control de miopia [Conference presentation abstract]. OPTOM 2024, Madrid, Spain.
⁷
Ohlendorf, A., et al. (2024, May 5-9). Myopia control efficacy through Emmetropic Progression Ratio:1-year of spectacle wear with cylindrical annular refractive elements (CARE) [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Seattle, WA, United States.

Download

ZEISS MyoCare portfolio: Efficacy confirmed across multiple sites, large cohorts, and various ethnic groups – Basic Digest

234 KB

Download
ZEISS MyoCare portfolio: Efficacy confirmed across multiple sites, large cohorts, and various ethnic groups – Expert Digest

373 KB

Download

German: ZEISS MyoCare Portfolio: Wirksamkeit bestätigt über mehrere Standorte, große Kohorten und verschiedene Ethnien - Expertenwissen

137 KB

Download